Lafem

Quick links to important sections

Lafem

Method of action: Antioxidant

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lafem

Quick Facts

Property Description
Active ingredient Lactic Acid (L-Lactic Acid)
Form Vaginal ovules, suppositories, or gel
Pharmacological class Acidifying agent, pH regulator
Common use Supporting Vaginal pH normalization
Origin Natural metabolite (bio-identical)

What Type of Medicine is Lafem and How is it Classified?

Lafem is a specialized, local-acting pharmaceutical preparation, typically supplied as Vaginal ovules or suppositories, designed for intravaginal use. Pharmacologically, it is classified as a highly targeted Acidifying agent and pH regulator. Its primary role is to chemically support the local ecosystem rather than acting as a broad-spectrum anti-infective treatment.

This classification is based on the mechanism of its active compound. The use of local lactic acid preparations is a method for maintaining the physiological vaginal pH, thereby sustaining the protective flora. This action reinforces the body's natural defense mechanisms by controlling the acidity level. Lafem is often positioned as an Over-the-Counter (OTC) option for women of reproductive age seeking to proactively maintain their flora.

Composition and Origin: The Role of Lactic Acid

The sole active ingredient [INN] in Lafem is Lactic Acid (L-Lactic Acid), which is integrated into a suitable pharmaceutical base for controlled local release. Lactic Acid is categorized as a natural metabolite, meaning it is a compound that is intrinsically produced by the dominant beneficial bacteria, Lactobacilli, within a healthy microflora.

By providing this bio-identical substance directly to the local area, the preparation supports the body's intrinsic processes. The application of this substance supports the natural colonization of protective bacteria after restoring the proper acidic conditions. Essentially, the preparation provides the essential chemical foundation needed for the body’s own protective bacteria to thrive.

General Purpose: Supporting the Natural Vaginal Microbiome

The overall purpose of Lafem is to manage and counteract dysbiosis by facilitating rapid Vaginal pH normalization. This action is paramount because the optimal acidic environment is the principal factor controlling the ecosystem’s health. A typical neutral use scenario for Lafem is following the completion of antibiotic courses, where Vaginal flora disturbance is common. By supplying the necessary Acidifying agent, the medicine creates the ideal environment to reinforce the growth and dominance of the beneficial Lactobacilli, leading to the establishment of eubiosis and strengthening the body's natural defensive barrier.

Regulatory References

  1. NIH Clinical Trials
  2. Lactic Acid - MedlinePlus

What side effects are possible with Lafem?

Possible Side Effects and Safety Information

The safety profile for Lactic Acid vaginal preparations, such as Lafem, is largely defined by localized reactions, which are officially classified by frequency based on controlled studies. All adverse reactions are documented in regulatory sources and categorized by System-Organ Class (SOC).


Frequency-Classified Adverse Reactions

The majority of side effects are confined to the application site and are categorized as common in regulatory labeling:

Classification Examples of Reactions (SOC Classification)
Most Common (ge 10%) Vulvovaginal burning sensation and pruritus (itching) (Administration Site Conditions)
Common (ge 2% to < 10%) Vulvovaginal discomfort, pain, and discharge (Administration Site Conditions; Reproductive System), as well as certain infections (e.g., mycotic infection, Urinary Tract Infection, Bacterial Vaginosis) (Infections and Infestations)

Discomfort, including burning and itching, in male partners following product use is also a documented safety note from clinical trials.


Clinically Significant and Serious Reactions

The regulatory safety profile includes documentation of clinically significant, though rare, events. The official labeling specifies Pyelonephritis (kidney infection) and other upper urinary tract infections (such as Cystitis) as serious adverse reactions that have occurred.

Population-Specific Safety Constraints

Official safety documents define specific limitations on use, which is a key part of the regulatory safety profile. The preparation is constrained in individuals with a history of recurrent Urinary Tract Infection (UTI) or existing urinary tract abnormalities due to the documented risk of ascending infection. Use is also restricted in individuals with known or suspected hypersensitivity to any component of the formulation. The most common local effects were generally mild and rarely led to discontinuation in clinical trials, distinguishing them from the explicit restrictions related to urinary tract risk.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Lafem, a local-acting Lactic Acid preparation, defines overdose concerns as strictly related to excessive local exposure at the application site, ruling out systemic toxicity.

Overdose manifestations are primarily confined to the local mucosa, presenting as an intensification of expected local effects.

Parameter Regulatory Statement
Documented Overdose Signs Intensified local irritation, burning sensation, erythema, and pain at the application site.
Systemic Risk Profile Not documented in official labels; systemic toxicity is excluded from the overdose profile.

The official prescribing information states that no specific antidote is known for Lactic Acid overdose. Management is centered on supportive procedures.

Mandatory Emergency Actions

The first step upon suspected overdose is to discontinue use immediately. Official guidance mandates that immediate medical attention must be sought if the local symptoms persist or worsen significantly despite stopping the product and performing simple supportive measures.

Officially described supportive measures include the irrigation or washing of the affected area to dilute the remaining active substance. Symptomatic and supportive treatment may be required to manage the local inflammation and pain.

Therapeutic Uses of Lafem

What Lafem Treats: Main Uses and Benefits

Lafem is commonly used to help with managing symptoms related to a disturbed acidic balance in the vaginal microflora. Its use supports the patient during difficult episodes by easing distress in situations where patients experience certain distressing symptoms linked to temporary pH elevation. The key therapeutic uses are primarily centered on supportive care for vaginal flora disturbance, recurrent episodes of pH-related symptoms, and maintaining balance after systemic antibiotics or the menstrual cycle.

Addressing Unpleasant Odor and Abnormal Discharge

Lafem is applied across domains where additional symptomatic support is needed to help address symptom clusters that may become disruptive, specifically the unpleasant or fishy vaginal odor and abnormal, thin discharge. It contributes to improved comfort during periods of heightened symptoms by supporting the restoration of the natural acidic environment, which may assist with easing these noticeable manifestations.

“This application helps manage the discomfort that often accompanies an unstable local environment.”

Supportive Care and Recurrence Management

The medication is considered relevant for easing the overall symptom load in individuals prone to recurrent episodes of symptoms linked to pH elevation. Its use helps to stabilize the acidic conditions, which supports the patient during difficult episodes and may assist with managing the frequency with which these symptoms return.


Quick Fact: Relief for pH-Related Symptoms

Property Description
Primary Goal Supporting pH stabilization
Used for managing Unpleasant odor and abnormal discharge
Common Use Context Post-antibiotic recovery, recurrent episodes
Patient Benefit Contributes to improved comfort and stability

Regulatory References

  1. National Institutes of Health (NIH) overview of Lactic Acid use for Bacterial Vaginosis

Eligibility and Restrictions for Use

Who Can and Cannot Use Lafem?

The official regulatory profile for Lafem establishes specific population eligibility rules regarding age, reproductive status, and pre-existing medical conditions. The medicine is indicated for use by females of reproductive potential, which encompasses adult women and adolescents 17 years of age and older.

Lafem is formally contraindicated in specific groups. Individuals with a known hypersensitivity or allergy to Lactic Acid or any component in the formulation must not use the medicine. Regulatory documents also state that use must be avoided in women with a history of recurrent urinary tract infection (UTI) or diagnosed urinary tract abnormalities.

Regarding age and physiological status, the product is not indicated for use in females before menarche (the start of menstruation). Use in post-menopausal women is generally considered not established, as the available clinical data is centered on the reproductive age group.

For physiological states, use should be discontinued during pregnancy. Conversely, use during lactation or breastfeeding is permitted, as systemic absorption of the active ingredient is considered minimal.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Lafem is defined by interactions that are strictly local in nature, reflecting its intravaginal route of administration as an acidifying agent. Regulatory documents confirm that due to minimal systemic absorption of Lactic Acid, there are no documented systemic pharmacokinetic interactions, including those mediated by CYP enzymes or drug transporters.

Documented Local Interactions and Restrictions

Interaction Type Restrictions as Documented in Official Labels
Pharmacodynamic Antagonism Co-administration with highly alkaline vaginal products (high pH) is restricted due to the risk of chemical neutralization of the active ingredient.
Timing-Based Interference Mandatory time separation is required between the administration of Lafem and any other intravaginal medicinal product (e.g., creams, ovules, or washouts).
Other Local Agents Co-administration with spermicidal preparations is restricted as the acidic environment created by Lafem may interfere with their intended local action.

These restrictions establish that the primary interaction concern is the potential for other local treatments to physically or chemically interfere with Lafem at the site of application. Official labeling confirms that no interactions with food, alcohol, herbal products, or systemic supplements have been documented.

Mechanism of Action

Direct Regulation of Local Acid-Base Homeostasis

Lafem's mechanism is a highly targeted physicochemical intervention that functions as a direct pH regulator. The active ingredient, Lactic Acid, acts as a proton donor (H^+). This interaction swiftly overloads the local buffering system, causing a rapid and localized pH reduction. This chemical action directly and immediately initiates the biological cascade required for the establishment of a stable local pH condition.


Selective Microbiome Modulation and Cascade

The resulting low pH creates selective pressure, which is the core of the biological mechanism. This acidity preferentially promotes the colonization and metabolic activity of acid-tolerant Lactobacilli and simultaneously suppresses non-acidophilic flora. This selective modulation establishes Lactobacilli dominance; this ecological shift constitutes the functional basis of the local epithelial defense and contributes to the overall maintenance of the micro-environment's equilibrium.


Constraints of the Physicochemical Mechanism

The mechanism's efficacy is biologically constrained by the local buffer capacity of any existing fluid, which can temporarily neutralize the acidifying effect. Furthermore, the action promotes growth, but it requires a minimal residual population of Lactobacilli to be present for the establishment of a physicochemical equilibrium.

Dosage and Administration Information

The administration of Lafem is strictly confined to the intravaginal route and is supplied either as a single ovule (pessary) or as a measured dose within a pre-filled applicator. The schedule of use is based on the application of a single, standardized dose per administration occasion.

For short-term usage, the medicine is typically administered once daily over a consecutive period, such as a 5- to 7-day course. Some patterns also permit an intermittent or as-needed schedule for ongoing use.

The standard protocol advises that Lafem be administered at bedtime while the user is lying down to maximize the time the product remains at the site of application. The ovule or gel should be inserted as deep as possible into the vagina. For user comfort, ovules may be moistened slightly with water prior to insertion. Used single-dose applicators must be disposed of immediately.

Administration is specifically not recommended during the menstrual period, and those days should be skipped if they interrupt a scheduled course. Due to the local nature of the application, generally, no dose adjustments are required for older adults or those with renal or hepatic impairment. Furthermore, the product is not indicated for use in the pediatric population prior to the start of menstruation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lafem (Lactic Acid)

Evidence for Managing Symptoms Related to Vaginal Flora Disturbance

Research exploring the use of Lactic Acid preparations has primarily focused on conditions characterized by fluctuating or episodic manifestations, such as those where pH elevation is associated with symptoms like unpleasant odor and discharge. The available research includes Randomized Controlled Trials (RCTs) and systematic reviews which compare the Lactic Acid product (ovules or gel) against an inactive comparator or were studied alongside standard antibiotic treatment. Studies focused on outcomes related to physical discomfort and patient-reported experiences, measuring shifts in Vaginal pH values and changes in microbiological assessment scores. These trials were typically conducted on women of reproductive age experiencing periods of heightened symptoms.

Findings describe measured temporary shifts in pH toward the acidic range observed in the studies. However, evidence remains limited regarding comparative research between Lactic Acid products and first-line antibiotic treatments for the initial symptomatic resolution of flora disturbance. Follow-up durations were typically limited to the short-term (around 7 to 14 days).

Research on Recurrence Management and Post-Antibiotic Recovery

Research has also explored the role of Lactic Acid products as a maintenance strategy, studying outcomes related to pH stability and the frequency of symptom recurrence following initial treatment. This research often involves Randomized Controlled Trials where Lactic Acid was studied for women with a history of recurrent episodes. These studies focused on long-term outcomes, such as monitoring the time until the first return of symptoms and the number of symptomatic episodes over defined time intervals, typically up to six months.

Findings describe measured patterns related to the stability of the vaginal environment when Lactic Acid was applied after initial treatment. A key limitation in recurrence trials is the difficulty in isolating the effects of the product from the body's natural recovery processes and the cycle of stability and flare-ups.

What Remains Uncertain and Areas for Future Research

Evidence quality varies across studies, and some comparative evidence is lacking or inconclusive. Data for certain groups remain insufficient, meaning the applicability of findings to all individuals may be limited. Longer follow-up durations are still needed to better understand the durability of the observed pH stability patterns. Findings describe group patterns, not personal outcomes, and study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Lafem (FAQ)


Q: Is Lafem the same type of medicine as similar drug names?

No, official product information indicates Lafem works as an acid-buffering preparation. Its mechanism is purely physicochemical—it maintains the vaginal pH in an acidic range (3.5–4.5). This action is distinct from hormonal or antibiotic drug mechanisms.


Q: Why do people sometimes use Lafem instead of other options?

According to official information, Lafem is sometimes chosen because of its mechanism. Use may be preferred due to its non-hormonal nature, and as an alternative to antibiotics, depending on the specific condition it is being used for.


Q: How quickly does Lafem generally start to work after I begin taking it?

Regulatory documents state that Lafem begins to work rapidly upon application. Its purpose is to quickly create or restore the desired acidic vaginal pH at the site of administration.


Q: What is the expected time frame for noticing the effects of Lafem?

While some local effects, such as a feeling of relief, may be felt quickly, full clinical or therapeutic outcomes are typically assessed over the standard course of therapy. This timeframe often aligns with the short follow-up periods used in clinical trials.


Q: Is Lafem suitable for use in older adults?

Official labeling establishes safety and effectiveness for females of reproductive potential. Specific data for non-reproductive populations, such as post-menopausal or elderly women, may not be included in the primary labeling for all preparations, focusing instead on the target demographic.


Q: Can individuals with a history of kidney problems use Lafem?

Regulatory warnings state that use of Lafem is restricted or contraindicated in individuals who have a history of recurrent urinary tract infections (UTIs) or other urinary tract abnormalities. This restriction is due to a documented risk of the infection ascending.


Q: Is Lafem available in different strengths or forms?

The product is generally supplied as a single, standardized dose (e.g., a 5-gram application) per unit. However, it is available in multiple forms such as gels, ovules, and suppositories.


Q: Is it normal to feel a mild headache when first starting Lafem?

According to the official product information on adverse reactions, headache is listed as a rare or less common side effect. The majority of reported effects are localized to the site of application.


Q: Do the side effects of Lafem usually go away after a few weeks?

Official regulatory documents indicate that the majority of common local adverse reactions are described as mild in nature. In clinical trials, the common local effects were described as generally mild and rarely led to discontinuation.


Q: Does taking Lafem require any special monitoring by a healthcare provider?

No specific blood tests or routine clinical monitoring are mandated for patients using the product. This is due to its local action and the fact that minimal systemic absorption is expected.


Q: Does Lafem affect sleep patterns?

Regulatory labeling on adverse reactions indicates that sleep changes (such as insomnia) are not listed as a common or serious side effect.


Q: Is it true that Lafem might cause changes in appetite?

Official product information on adverse reactions states that changes in appetite are not documented as a common or serious adverse reaction.


Q: Is Lafem known to cause dry mouth?

Based on regulatory labeling, dry mouth is not listed as a common or serious adverse reaction.


Q: Can a person stop taking Lafem abruptly?

For products used over a set treatment course, stopping the medicine before the full course is completed may result in the desired therapeutic benefit not being achieved. Official guidance on use outlines the necessary duration for the intended effect.


Q: Is Lafem approved for use in countries outside of the US?

Regulatory data confirms that the active ingredient (Lactic Acid) is used in products approved in multiple jurisdictions worldwide. This includes the United States (FDA) and other countries.


Q: Is Lafem addictive or habit-forming?

Official regulatory labeling contains no warnings or statements regarding abuse potential, physical dependence, or being habit-forming.


Q: How long does Lafem stay in the body after the last dose?

Due to the product's local action and minimal systemic absorption, detailed pharmacokinetic information, such as elimination half-life, is not typically reported in the regulatory documentation.


Q: Does Lafem contain gluten or lactose?

Regulatory documentation lists the inactive ingredients (excipients). The full list of inactive ingredients is available in the official labeling for those who need to review it due to specific allergies or sensitivities.


Q: Are there common signs that Lafem is working?

Common signs that the medicine is having its intended effect include patient-reported improvement in symptoms. This includes relief of odor, discomfort, or abnormal discharge, which aligns with clinical trial endpoints.


Q: Can Lafem be split or crushed if a person has trouble swallowing?

Lafem is a vaginal gel or ovule which is applied locally via an applicator and is not intended for oral consumption. Ovules and suppositories are designed to be inserted whole and are not authorized to be cut, split, or crushed.


Q: What is the risk of a severe allergic reaction to Lafem?

Severe allergic reactions (hypersensitivity) are rarely documented; regulatory data indicates one suspected case was reported in clinical trials involving over 2,800 participants.


Q: Does Lafem have any effect on driving or operating machinery?

Due to the medicine's local action and the absence of common central nervous system (CNS) side effects, no specific warnings regarding driving or operating machinery are included in the labeling.


Q: Is Lafem commonly associated with weight changes?

Based on official product information on adverse reactions, weight changes are not listed as a common or serious adverse reaction in the regulatory labeling.

How should Lafem be stored and disposed of?

How to Store and Dispose of Lafem?

The storage of Lafem must strictly follow regulatory guidance to maintain product integrity. The medicine must be stored at a controlled room temperature not exceeding 25 C (77 F).

It is mandatory to keep the product in its original packaging and protect it from both excessive heat and moisture. To prevent physical degradation of the ovules, the product must not be refrigerated or frozen. All medicine must be stored out of the sight and reach of children.

For disposal, unused or expired Lafem must not be flushed into wastewater. Government health authorities recommend using an official drug take-back program. If a program is unavailable, mix the medicine with an undesirable substance (such as used coffee grounds) in a sealed container before disposal in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lafem found in:

A-Z Index: